Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 6 examiners • 0 of 8 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. maintains a prosecution profile with 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct examiners and 6 distinct art units, indicating a broad range of biological research currently under review. This level of activity suggests a significant commitment to securing intellectual property in multiple technical niches. The distribution across 6 distinct art units allows the company to receive feedback from various specialized sections of the USPTO.
The busiest examiner for the portfolio is MONTANARI, DAVID A, who is responsible for 3 pending office actions. This concentration means that while the company deals with several examiners, this individual manages a notable portion of the 8 pending office actions. Practitioners should prioritize understanding the specific preferences of this examiner, as their decisions will have a larger impact on the portfolio's immediate success compared to the other examiners involved. Managing the 3 pending office actions under this examiner requires a focused strategy to ensure consistency across the company's pharmaceutical applications.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 3 | 64.8% | +49.0% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| ARON, KIMBERLY A | 1 | 54.7% | +34.3% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
| ABBOTT, KODYE LEE | 1 | 54.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025990 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R | MONTANARI, DAVID A | 20d |
| 18025302 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 | MONTANARI, DAVID A | 29d |
| 18702039 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | KIM, TAEYOON | — |
| 17631048 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 | ABBOTT, KODYE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025990 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R | MONTANARI, DAVID A | 20d |
| 18025302 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 | MONTANARI, DAVID A | 29d |
| 18644615 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH COMMON LIGHT CHAIN IMMUNOGLOBULIN LOCUS | MONTANARI, DAVID A | — |
| 18643334 | MODIFIED IMMUNOGLOBULINS | OUSPENSKI, ILIA I | — |
| 18702039 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | KIM, TAEYOON | — |
| 18634364 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS | ARON, KIMBERLY A | — |
| 17631048 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1644 | 1 |
| 1631 | 1 |
| 1633 | 1 |
| 1638 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18644615 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH COMMON LIGHT CHAIN IMMUNOGLOBULIN LOCUS | MONTANARI, DAVID A | — | §112 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18643334 | MODIFIED IMMUNOGLOBULINS | OUSPENSKI, ILIA I | 1644 | §102§112DP | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18702039 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | KIM, TAEYOON | 1631 | §102§103 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18634364 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS | ARON, KIMBERLY A | 1633 | §102§103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18273631 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 28d overdue | Pending | Jul 21, 2023 |
| 18025990 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R | MONTANARI, DAVID A | 1632 | §102§103 | Final Rejection | 20d | Pending | Mar 13, 2023 |
| 18025302 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 | MONTANARI, DAVID A | 1632 | §102§103 | Final Rejection | 29d | Pending | Mar 08, 2023 |
| 17631048 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Jan 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. has 8 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
David A Montanari has the most, with 3 of BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
